Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture
Cadarette SM et al. - Differences in fracture risk between risedronate or raloxifene and alendronate were small. Nasal calcitonin recipients may have a higher risk for nonvertebral fractures compared with alendronate recipients. Methods- Aim was to compare the relative effectiveness of osteoporosis treatments to reduce nonvertebral fracture risk among older adults
- 43,135 new recipients of oral bisphosphonates, nasal calcitonin, and raloxifene
- The mean age was 79 yrs, and 96% were women
- The primary outcome was nonvertebral fracture within 12 mos of treatment initiation
- Alendronate was the reference category in all analyses
Results- A total of 1051 nonvertebral fractures were observed within 12 mos
- No large differences in fracture risk were found between risedronate or raloxifene and alendronate
- Among those with a fracture history, raloxifene recipients experienced more nonvertebral fractures within 12 mos vs alendronate recipients
- Pts who received calcitonin experienced more nonvertebral fractures than those who received alendronate
[more...]
|
|
|
